MDPI and ACS Style
Gardner, F.P.; Wainberg, Z.A.; Fountzilas, C.; Bahary, N.; Womack, M.S.; Macarulla, T.; Garrido-Laguna, I.; Peterson, P.M.; Borazanci, E.; Johnson, M.;
et al. Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 1b/2 Trial of Nabpaclitaxel + Gemcitabine ± Olaratumab in Treatment-Naïve Participants with Metastatic Pancreatic Cancer. Cancers 2024, 16, 1323.
https://doi.org/10.3390/cancers16071323
AMA Style
Gardner FP, Wainberg ZA, Fountzilas C, Bahary N, Womack MS, Macarulla T, Garrido-Laguna I, Peterson PM, Borazanci E, Johnson M,
et al. Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 1b/2 Trial of Nabpaclitaxel + Gemcitabine ± Olaratumab in Treatment-Naïve Participants with Metastatic Pancreatic Cancer. Cancers. 2024; 16(7):1323.
https://doi.org/10.3390/cancers16071323
Chicago/Turabian Style
Gardner, Faithlore P., Zev A. Wainberg, Christos Fountzilas, Nathan Bahary, Mark S. Womack, Teresa Macarulla, Ignacio Garrido-Laguna, Patrick M. Peterson, Erkut Borazanci, Melissa Johnson,
and et al. 2024. "Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 1b/2 Trial of Nabpaclitaxel + Gemcitabine ± Olaratumab in Treatment-Naïve Participants with Metastatic Pancreatic Cancer" Cancers 16, no. 7: 1323.
https://doi.org/10.3390/cancers16071323
